PHARMASPIRE - Volume 15, Issue 04, 2023, October-December

Pages: 283-295

Date of Publication: 17-Feb-2024

Print Article   Download XML  Download PDF

An insight on mechanism and management of kidney stones and its recurrence

Author: Divyanshu Rajput, Tanpreet Kaur Badwal, Shreya Gupta, Rajendra Kumar

Category: Pharmacy Practice

Abstract:

Kidney stones (calculi) comprise mineral concretions which can form in both renal calyces and pelvis and can be free floating or associated with the renal papillae. It is an emerging urological condition that affects around 12% of the world’s population. Globally, the prevalence and recurrence of kidney stone disease are increasing, and there are limited effective treatment options. I manifest a brief general overview and then concentrate on risk factors, pathophysiology, and medical treatment of kidney stones. The major component of most stones is calcium oxalate, and many of them develop on a foundation of calcium phosphate known as Randall’s plaques, which are located on the renal papillary surface. The mechanism of stone formation is a complicated process that involves multiple physicochemical phenomena such as supersaturation, nucleation, growth, aggregation, and retention of urinary stone ingredients inside tubular cells. Cellular damage is also thought to enhance particle retention on renal papillary surfaces. There is currently no effective treatment or prevention for kidney stone recurrence. Recurrence prevention required behavioral and nutritional interventions, as significantly as pharmaceutical therapies tailored to the kind of stone. There is a great demand for recurrence prevention, which necessitates a deeper knowledge of the processes involved in the development of stones to design more effective medications. Open surgical lithotomy has given way to minimally invasive endourological procedures for the treatment of symptomatic kidney stones, resulting in lower patient morbidity, increased stone-free rates, and enhanced quality of life. As a result, furthering our knowledge of the biology of kidney stone development is a research focus for treating urolithiasis with novel medications.

Keywords: Kidney stones, Mechanism of kidney stones, Prevention, Recurrence, Treatment

DOI: 10.56933/Pharmaspire.2023.15143

DOI URL: https://doi.org/10.56933/Pharmaspire.2023.15143

References:

1. Khan SR, Pearle MS, Robertson WG, Gambaro G, Canales BK, Doizi S, et al. Kidney stones. Nat Rev Dis Primers 2016;2:16008.
2. Knoll T. Epidemiology, pathogenesis, and pathophysiology of urolithiasis. Eur Urol Suppl 2010;9:802-6.
3. Stamatelou KK, Francis ME, Jones CA, Nyberg LM, Curhan GC. Time trends in reported prevalence of kidney stones in the United States: 1976-1994. Kidney Int 2003;63:1817-23.
4. Moe OW. Kidney stones: Pathophysiology and medical management. Lancet 2006;367:333-44.
5. Edvardsson VO, Indridason OS, Haraldsson G, Kjartansson O, Palsson R. Temporal trends in the incidence of kidney stone disease. Kidney Int 2013;83:146-52.
6. Finlayson B. Physicochemical aspects of urolithiasis. Kidney Int 1978;13:344-60.
7. Afsar B, Kiremit MC, Sag AA, Tarim K, Acar O, Esen T, et al. The role of sodium intake in nephrolithiasis: Epidemiology, pathogenesis, and future directions. Eur J Intern Med 2016;35:16-9.
8. Coe FL, Parks JH, Asplin JR. The pathogenesis and treatment of kidney stones. N Engl J Med 1993;327:1141-52.
9. Robertson WG, Heyburn PJ, Peacock M, Hanes FA, Swaminathan R. The effect of high animal protein intake on the risk of calcium stone-formation in the urinary tract. Clin Sci (Lond) 1979;57:285-8.
10. Kumar SB, Kumar GK, Srinivasa V, Bilal S. A review on urolithiasis. Int J Univ Pharm Life Sci 2012;2:269-80.
11. Teichman JM. Clinical practice. Acute renal colic from ureteral calculus. N Engl J Med 2004;350:684-93.
12. Vaughan LE, Enders FT, Lieske JC, Pais VM, Rivera ME, Mehta RA, et al. Predictors of symptomatic kidney stone recurrence after the first and subsequent episodes. Mayo Clin Proc 2019;94:202-10.
13. Joseph KC, Parekh BB, Joshi MJ. Inhibition of growth of urinary type calcium hydrogen phosphate dihydrate crystals by tartaric acid and tamarind. Curr Sci 2005;88:1232-8.
14. Zhang Y, Wei C, Pokhrel G, Liu X, Ouyang W, Gan J, et al. Mini-percutaneous nephrolithotomy with ureter catheter: A safe and effective form of mPCNL offers better quality of life. Urol Int 2019;102:160-6.
15. Alelign T, Petros B. Kidney stone disease: An update on current concepts. Adv Urol 2018;2018:3068365.
16. Chhiber N, Sharma M, Kaur T, Singla SK. Mineralization in health and mechanism of kidney stone formation. Int J Pharm Sci Invent 2014;3:25-31.
17. Barbas C, García A, Saavedra L, Muros M. Urinary analysis of nephrolithiasis markers. J Chromatogr B Analyt Technol Biomed Life Sci 2002;781:433-55.
18. Chaudhary A, Singla SK, Tandon C. In vitro evaluation of Terminalia arjuna on calcium phosphate and calcium oxalate crystallization. Indian J Pharm Sci 2010;72:340-5.
19. Bensatal A, Ouahrani MR. Inhibition of crystallization of calcium oxalate by the extraction of Tamarix gallica L. Urol Res 2008;36:283-7.
20. Dal Moro F, Mancini M, Tavolini IM, De Marco V, Bassi P. Cellular and molecular gateways to urolithiasis: A new insight. Urol Int 2005;74:193-7.
21. Dursun M, Otunctemur A, Ozbek E. Kidney stones and ceftriaxone. Eur Med J Urol 2015;3:68-74.
22. Giannossi ML, Summa V. A Review of Pathological Biomineral Analysis Techniques and Classification Schemes. An Introduction to the Study of Mineralogy. London: IntechOpen; 2012. p. 123-46.
23. Griffith DP. Struvite stones. Kidney Int 1978;13:372-82.
24. Ahmed K, Dasgupta P, Khan MS. Cystine calculi: Challenging group of stones. Postgrad Med J 2006;82:799-801.
25. Tosukhowong P, Boonla C, Ratchanon S, Tanthanuch M, Poonpirome K, Supataravanich P, et al. Crystalline composition and etiologic factors of kidney stone in Thailand: Update 2007. Asian Biomed 2007;1:87-95.
26. Sakhaee K, Maalouf NM, Sinnott B. Kidney stones 2012: Pathogenesis, diagnosis, and management. J Clin Endocrinol Metab 2012;97:1847-60.
27. Basavaraj DR, Biyani CS, Browning AJ, Cartledge JJ. The role of urinary kidney stone inhibitors and promoters in the pathogenesis of calcium containing renal stones. EAU EBU Update Ser 2007;5:126-36.
28. Malhotra KK. Medical aspects of renal stones. J Indian Acad Clin Med 2008;9:282-6.
29. Aggarwal KP, Narula S, Kakkar M, Tandon C. Nephrolithiasis: Molecular mechanism of renal stone formation and the critical role played by modulators. Biomed Res Int 2013;2013:292953.
30. Ahmed S, Hasan MM, Mahmood ZA. In vitro urolithiasis models: An evaluation of prophylactic management against kidney stones. J Pharmacogn Phytochem 2016;5:28.
31. Ratkalkar VN, Kleinman JG. Mechanisms of stone formation. Clin Rev Bone Mineral Metab 2011;9:187-97.
32. Khan SR, Atmani F, Glenton P, Hou Z, Talham DR, Khurshid M. Lipids and membranes in the organic matrix of urinary calcific crystals and stones. Calcif Tissue Int 1996;59:357-65.
33. Courbebaisse M, Prot-Bertoye C, Bertocchio JP, Baron S, Maruani G, Briand S, et al. Nephrolithiasis of adult: From mechanisms to preventive medical treatment. Rev Med Interne 2016;38:44-52.
34. Tsujihata M. Mechanism of calcium oxalate renal stone formation and renal tubular cell injury. Int J Urol 2008;15:115-20.
35. Verkoelen CF, van Der Boom BG, Romijn JC. Identification of hyaluronan as a crystal-binding molecule at the surface of migrating and proliferating MDCK cells. Kidney Int 2000;58:1045-54.
36. Moryama MT, Domiki C, Miyazawa K, Tanaka T, Suzuki K. Effects of oxalate exposure on Madin-Darby canine kidney cells in culture: Renal prothrombin fragment-1 mRNA expression. Urol Res 2005;33:470-5.
37. Khan SR, Glenton PA, Backov R, Talham DR. Presence of lipids in urine, crystals and stones: Implications for the formation of kidney stones. Kidney Int 2002;62:2062-72.
38. Khan SR, Thamilselvan S. Nephrolithiasis: A consequence of renal epithelial cell exposure to oxalate and calcium oxalate crystals. Mol Urol 2000;4:305-12.
39. Hackett RL, Shevock PN, Khan SR. Madin-Darby canine kidney cells are injured by exposure to oxalate and to calcium oxalate crystals. Urol Res 1994;22:197-203.
40. Fasano JM, Khan SR. Intratubular crystallization of calcium oxalate in the presence of membrane vesicles: An in vitro study. Kidney Int 2001;59:169-78.
41. Rashed T, Menon M, Thamilselvan S. Molecular mechanism of oxalate-induced free radical production and glutathione redox imbalance in renal epithelial cells: Effect of antioxidants. Am J Nephrol 2004;24:557-68.
42. Chaturvedi LS, Koul S, Sekhon A, Bhandari A, Menon M, Koul HK. Oxalate selectively activates p38 mitogenactivated protein kinase and c-Jun N-terminal kinase signal transduction pathways in renal epithelial cells. J Biol Chem 2002;277:13321-30.
43. Peerapen P, Thongboonkerd V. p38 MAPK mediates calcium oxalate crystal-induced tight junction disruption in distal renal tubular epithelial cells. Sci Rep 2013;3:1041.
44. Koul S, Khandrika L, Pshak TJ, Iguchi N, Pal M, Steffan JJ, et al. Oxalate upregulates expression of IL-2Rβ and activates IL-2R signaling in HK-2 cells, a line of human renal epithelial cells. Am J Physiol Renal Physiol 2014;306:F1039-46.
45. Hsieh N, Shih CH, Chen HY, Wu MC, Chen WC, Li CW. Effects of Tamm-Horsfall protein on the protection of MCDK cells from oxalate induced free radical injury. Urol Res 2003;31:10-6.
46. Sayer JA. The genetics of nephrolithiasis. Nephron Exp Nephrol 2008;110:e37-43.
47. Evan AP. Physiopathology and etiology of stone formation in the kidney and the urinary tract. Pediatr Nephrol 2010;25:831-41.
48. Daudon M, Bazin D, Letavernier E. Randall’s plaque as the origin of calcium oxalate kidney stones. Urolithiasis 2015;43 Suppl 1:5-11.
49. Yuen JW, Gohel MD, Poon NW, Shum DK, Tam PC, Au DW. The initial and subsequent inflammatory events during calcium oxalate lithiasis. Clin Chim Acta 2010;411:1018-26.
50. Khan SR. Reactive oxygen species, inflammation and calcium oxalate nephrolithiasis. Transl Androl Urol 2014;3:256-76.
51. Khan SR, Kok DJ. Modulators of urinary stone formation. Front Biosci 2004;9:1450-82.
52. Çak?ro?lu B, Eyyupo?lu E, Hazar AI, Uyanik BS, Nuho?lu B. Metabolic assessment of recurrent and first renal calcium oxalate stone formers. Arch Ital Urol Androl 2016;88:101-5.
53. Marengo SR, Romani AM. Oxalate in renal stone disease: The terminal metabolite that just won’t go away. Nat Clin Pract Nephrol 2008;4:368-77.
54. Gambaro G, Croppi E, Coe F, Lingeman J, Moe O, Worcester E, et al. Metabolic diagnosis and medical prevention of calcium nephrolithiasis and its systemic manifestations: A consensus statement. J Nephrol 2016;29:715-34.
55. Ordon M, Urbach D, Mamdani M, Saskin R, D’A Honey RJ, Pace KT. The surgical management of kidney stone disease: A population based time series analysis. J Urol 2014;192:1450-6.
56. Wignall GR, Canales BK, Denstedt JD, Monga M. Minimally invasive approaches to upper urinary tract urolithiasis. Urol Clin North Am 2008;35:441-54, viii.
57. Kamphuis GM, Baard J, Westendarp M, de la Rosette JJ. Lessons learned from the CROES percutaneous nephrolithotomy global study. World J Urology 2015;33:223-33.
58. Preminger GM, Clayman RV, Hardeman SW, Franklin J, Curry T, Peters PC. Percutaneous nephrostolithotomy vs open surgery for renal calculi: A comparative study. JAMA 1985;254:1054-8.
59. Holdgate A, Pollock T. Nonsteroidal anti-inflammatory drugs (NSAIDs) versus opioids for acute renal colic. Cochrane Database Syst Rev 2004;2004:CD004137.
60. Serinken M, Eken C, Turkcuer I, Elicabuk H, Uyanik E, Schultz CH. Intravenous paracetamol versus morphine for renal colic in the emergency department: A randomised double-blind controlled trial. Emerg Med J 2012;29:902-5.
61. Worster AS, Bhanich Supapol W. Fluids and diuretics for acute ureteric colic. Cochrane Database Syst Rev 2012;2:CD004926.
62. Pickard R, Starr K, MacLennan G, Lam T, Thomas R, Burr J, et al. Medical expulsive therapy in adults with ureteric colic: A multicentre, randomised, placebocontrolled trial. Lancet 2015;386:341-9.
63. Moran ME, Abrahams HM, Burday DE, Greene TD. Utility of oral dissolution therapy in the management of referred patients with secondarily treated uric acid stones. Urology 2002;59:206-10.
64. Gonzalez RD, Whiting BM, Canales BK. The history of kidney stone dissolution therapy: 50 years of optimism and frustration with renacidin. J Endourol 2012;26:110-8.
65. Samal L, Pattanaik AK, Mishra C, Maharana BR, Sarangi LN, Baithalu RK. Nutritional stretegies to prevent urolithiasis in animals. Vet World 2011;4:142.
66. Heilberg IP, Schor N. Renal stone disease: Causes, evaluation and medical treatment. Arq Bras Endocrinol Metabol 2006;50:823-31.
67. Xu H, Zisman AL, Coe FL, Worcester EM. Kidney stones: An update on current pharmacological management and future directions. Expert Opin Pharmacother 2013;14:435-47.
68. Park S, Pearle MS. Pathophysiology and management of calcium stones. Urol Clin North Am 2007;34:323-34.
69. Tiselius HG. Stone incidence and prevention. Braz J Urol 2000;26:452-62.
70. Frassetto L, Kohlstadt I. Treatment and prevention of kidney stones: An update. Am Fam Physician 2011;84:1234-42.